Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.

Abstract:

:Antiviral therapy has been shown to improve the prognosis of hepatitis B virus (HBV) DNA-positive hepatocellular carcinoma (HCC) after radical treatment, but antiviral treatments require further optimization. This study aimed to evaluate the efficacies of different antiviral strategies with HCC patients after hepatectomy/ablation. This prospective, randomized, controlled and multi-centre trial enrolled HBV DNA-positive primary HCC patients after hepatectomy/ablation between January 2007 and January 2009. Patients were divided into four groups: early combination (entecavir plus Peg-interferon [IFN]α-2a co-administration during year 1); late combination (addition of Peg-IFNα-2a for 48 weeks after 1 year of entecavir); nucleos(t)ide analogue[NA] monotherapy; and non-antiviral treatment. Primary endpoints included recurrence-free survival and overall survival. A total of 447 patients were enrolled. The 2-year and 8-year recurrence-free survival and 8-year overall survival rates were significantly higher in the early combination group than in the other two antiviral groups (P < .05). After 48-week treatment, more patients achieved an HBsAg reduction >1500 IU/mL and the mean HBsAg level was significantly lower in the early combination group compared with the late combination and NA monotherapy groups (P < .05). Multivariate analysis showed that early combination therapy and a reduction in HBsAg by >1500 IU/mL after 48 weeks of therapy correlated with reduced mortality and disease recurrence. Early introduction of combination antiviral treatment may represent a more effective therapeutic strategy for patients with HBV DNA-positive HCC after hepatectomy/ablation. A reduction in HBsAg by >1500 IU/mL after 48-week treatment is associated with reduced mortality and disease recurrence of HBV DNA-positive HCC patients after hepatectomy/ablation.

journal_name

J Viral Hepat

authors

Qi W,Zhang Q,Xu Y,Wang X,Yu F,Zhang Y,Zhao P,Guo H,Zhou C,Wang Z,Sun Y,Liu L,Xuan W,Wang J

doi

10.1111/jvh.13236

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

387-396

issue

4

eissn

1352-0504

issn

1365-2893

journal_volume

27

pub_type

杂志文章
  • Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

    abstract::Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case finding, referral, treatment uptake and retention in care. Using data from the sentinel surveillance of blood-borne viru...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12844

    authors: Simmons R,Ireland G,Irving W,Hickman M,Sabin C,Ijaz S,Ramsay M,Lattimore S,Mandal S

    更新日期:2018-05-01 00:00:00

  • Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.

    abstract::The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German He...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13280

    authors: Knop V,Mauss S,Goeser T,Geier A,Zimmermann T,Herzer K,Postel N,Friedrich-Rust M,Hofmann WP,German Hepatitis C-Registry.

    更新日期:2020-07-01 00:00:00

  • GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

    abstract::GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-associated variants (RAVs). In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/jvh.12527

    authors: Rodriguez-Torres M,Glass S,Hill J,Freilich B,Hassman D,Di Bisceglie AM,Taylor JG,Kirby BJ,Dvory-Sobol H,Yang JC,An D,Stamm LM,Brainard DM,Kim S,Krefetz D,Smith W,Marbury T,Lawitz E

    更新日期:2016-08-01 00:00:00

  • The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.

    abstract::We evaluated the effect of sustained virologic response (SVR) from direct-acting antiviral (DAA)- and interferon-based treatments on hepatocellular carcinoma (HCC) risk in a large population-based cohort in Canada. We used data from the BC Hepatitis Testers Cohort, which includes ~1.3 million individuals tested for HC...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13295

    authors: Janjua NZ,Wong S,Darvishian M,Butt ZA,Yu A,Binka M,Alvarez M,Woods R,Yoshida EM,Ramji A,Feld J,Krajden M

    更新日期:2020-08-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group.

    abstract::Chronic non-A, non-B hepatitis (NANBH) is a common and often progressive liver disease. Based on current serological tests, hepatitis C virus (HCV) infection is responsible for most cases. Interferon-alpha (IFN) treatment at a dose of 3 x 10(6) units given three times per week for 24 weeks has been shown to be effecti...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.1994.tb00062.x

    authors: Davis GL,Lindsay K,Albrecht J,Bodenheimer HC Jr,Balart LA,Perrillo RP,Dienstag JL,Tamburro C,Schiff ER,Carey W

    更新日期:1994-01-01 00:00:00

  • Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.

    abstract::We compared Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+ -M2BP) levels between patients with chronic hepatitis B (n=249) and chronic hepatitis C (n=386) based on the degree of liver fibrosis. We examined WFA+ -M2BP levels in patients with F4 (cirrhosis), F3 or more (advanced fibrosis) and F2 or ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12575

    authors: Nishikawa H,Enomoto H,Iwata Y,Kishino K,Shimono Y,Hasegawa K,Nakano C,Takata R,Nishimura T,Yoh K,Ishii A,Aizawa N,Sakai Y,Ikeda N,Takashima T,Iijima H,Nishiguchi S

    更新日期:2016-12-01 00:00:00

  • How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?

    abstract::Chronic hepatitis C represents a major cause of progressive liver disease that can eventually evolve into cirrhosis and its end-stage complications. Formation and accumulation of fibrosis in the liver is the common pathway that leads to evolutive liver disease. Precise staging of liver fibrosis is essential for patien...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01518.x

    authors: Sebastiani G,Alberti A

    更新日期:2012-01-01 00:00:00

  • Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.

    abstract::In a previously reported randomized controlled trial of interferon-alpha (IFN-alpha) for chronic hepatitis B, we found a significant difference in response between Chinese adults with elevated vs normal pretreatment aminotransferase (ALT) levels. The aim of this study was to determine the correlation between serum hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00098.x

    authors: Lok AS,Ghany MG,Watson G,Ayola B

    更新日期:1998-05-01 00:00:00

  • Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

    abstract::Hepatitis C virus (HCV) is commonly transmitted by intravenous drug use (IDU) but drug users are under represented in many treatment cohorts, this is because of the assumption of lowered treatment success. We assessed HCV treatment outcomes in active intravenous drug users and patients on opiate substitution therapy. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01446.x

    authors: Jafferbhoy H,Miller MH,Dunbar JK,Tait J,McLeod S,Dillon JF

    更新日期:2012-02-01 00:00:00

  • Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.

    abstract::Significant advances have been made, during the last 5 years, in the treatment of chronic hepatitis B. Several new antiviral agents: lamivudine, famciclovir, lobucavir and adefovir, have been shown to be safe and effective in inhibiting hepatitis B virus (HBV) replication. These compounds can be administered orally an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00160.x

    authors: Hussain M,Lok AS

    更新日期:1999-05-01 00:00:00

  • Potential risk of zoonotic transmission from young swine to human: seroepidemiological and genetic characterization of hepatitis E virus in human and various animals in Beijing, China.

    abstract::The aim of this study was to further investigate the prevalence of infection and genotype of hepatitis E virus (HEV) among different species of animals, people whose works are related to pigs and the general population in the suburb of Beijing, China. Serum and faecal samples were collected from 10 animal species and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01472.x

    authors: Geng J,Wang L,Wang X,Fu H,Bu Q,Liu P,Zhu Y,Wang M,Sui Y,Zhuang H

    更新日期:2011-10-01 00:00:00

  • T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients.

    abstract::Limited data suggest that low T-helper cell levels may be observed in hepatitis C virus (HCV) monoinfected patients with decompensated liver disease. We sought to determine the distribution and relationship of T-helper cells (CD4) to liver fibrosis in HCV-monoinfected patients before and during pegylated interferon (P...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01173.x

    authors: Rashkin S,Rouster S,Goodman ZD,Sherman KE

    更新日期:2010-03-01 00:00:00

  • Dietary alterations due to perceptions in acute viral hepatitis lead to sub-optimal calorie intake and increased length of hospitalization.

    abstract::Although there are no dietary restrictions recommended in acute viral hepatitis (AVH), there is an altered food intake, probably because of perceptions and traditional nutritional practices, leading to sub-optimal intake and poorer clinical outcome. Therefore, we aimed to determine nutritional intake of AVH patients b...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01184.x

    authors: Sathiaraj E,Chutke M,Mahurkar S,Nagaraja Rao P,Nageshwar Reddy D

    更新日期:2010-05-01 00:00:00

  • Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.

    abstract::Treatment of chronic hepatitis B has been greatly improved by the use of lamivudine, but mutations occur in the polymerase region of hepatitis B virus (HBV) and lamivudine-resistant mutants frequently develop. The emergence of lamivudine-resistant strains of HBV is a problem for treating chronic hepatitis B using lami...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00559.x

    authors: Natsuizaka M,Hige S,Ono Y,Ogawa K,Nakanishi M,Chuma M,Yoshida S,Asaka M

    更新日期:2005-03-01 00:00:00

  • Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.

    abstract::The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants. All patients treated with ADV for at least 12 months were evaluated for virological...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00966.x

    authors: Gallego A,Sheldon J,García-Samaniego J,Margall N,Romero M,Hornillos P,Soriano V,Enrĺquez J

    更新日期:2008-05-01 00:00:00

  • Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.

    abstract::Circulating microRNAs (miRNA) have been intensely investigated as biomarkers in disease and therapy. Several studies have identified miR-122 as an important regulator of HCV replication. The effect of new therapies that directly target the HCV replication life cycle on circulating microRNA levels has not been elucidat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12470

    authors: Waring JF,Dumas EO,Abel S,Coakley E,Cohen DE,Davis JW,Podsadecki T,Dutta S

    更新日期:2016-02-01 00:00:00

  • The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.

    abstract::Hepatitis delta virus (HDV) RNA editing controls the formation of hepatitis-delta-antigen-S and -L and therefore indirectly regulates HDV replication. Editing is thought to be catalysed by the adenosine deaminase acting on RNA1 (ADAR1) of which two different forms exist, interferon (IFN)-alpha-inducible ADAR1-L and co...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00663.x

    authors: Hartwig D,Schütte C,Warnecke J,Dorn I,Hennig H,Kirchner H,Schlenke P

    更新日期:2006-03-01 00:00:00

  • Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

    abstract::Liver damage may result from multiple factors in HIV-infected patients. The availability of reliable noninvasive tools to measure liver fibrosis has permitted the screening of large patient populations. Cross-sectional study of all consecutive HIV outpatients who underwent examination by transient elastometry (FibroSc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01261.x

    authors: Blanco F,Barreiro P,Ryan P,Vispo E,Martín-Carbonero L,Tuma P,Labarga P,Medrano J,González-Lahoz J,Soriano V

    更新日期:2011-01-01 00:00:00

  • High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.

    abstract::To determine the relationship between p53 altered expression and p53 mutations in hepatocellular carcinoma (HCC), we analysed p53 protein immunohistochemically and assessed the presence of mutations in exons 4-8 of the p53 gene using SSCP assay in 117 HCCs corresponding to 78 patients. We also determined the relations...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00541.x

    authors: Anzola M,Saiz A,Cuevas N,Lopez-Martinez M,Martinez de Pancorbo MA,Burgos JJ

    更新日期:2004-11-01 00:00:00

  • Immune modulation by the hepatitis C virus core protein.

    abstract::Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral pers...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12675

    authors: Fernández-Ponce C,Dominguez-Villar M,Muñoz-Miranda JP,Arbulo-Echevarria MM,Litrán R,Aguado E,García-Cozar F

    更新日期:2017-05-01 00:00:00

  • Hepatitis E virus infection among animals in northern India: an unlikely source of human disease.

    abstract::Hepatitis E virus (HEV) is a major cause of acute hepatitis in many developing countries. Based on data from nonendemic regions, an animal reservoir of HEV has been proposed; however, data from HEV-endemic regions are limited. We tested sera from 200 pigs, 98 chickens, 86 goats, 58 sheep and 30 buffaloes for anti-HEV ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00815.x

    authors: Shukla P,Chauhan UK,Naik S,Anderson D,Aggarwal R

    更新日期:2007-05-01 00:00:00

  • Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.

    abstract::Hepatitis C virus (HCV) chronically infects about 200 million individuals worldwide and leads to severe liver and lymphatic diseases. HCV circulates in the serum, associated with apoB-containing lipoproteins. Platelet-activating factor (PAF), a pro-inflammatory mediator, is mainly modulated by plasma PAF-acetylhydrola...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00766.x

    authors: Caini P,Guerra CT,Giannini C,Giannelli F,Gragnani L,Petrarca A,Solazzo V,Monti M,Laffi G,Zignego AL

    更新日期:2007-01-01 00:00:00

  • Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.

    abstract::Obesity and insulin resistance have been reported as negative predictors for sustained virological response (SVR) in hepatitis C virus (HCV) genotype 1 infected patients treated with pegylated interferon-α plus ribavirin. They are also known to affect serum levels of several cytokines including adipocytokines. But the...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01516.x

    authors: Miki D,Ohishi W,Ochi H,Hayes CN,Abe H,Tsuge M,Imamura M,Kamatani N,Nakamura Y,Chayama K

    更新日期:2012-02-01 00:00:00

  • Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.

    abstract::Chronic hepatitis B virus (HBV)-infected patients with liver failure have a poor prognosis, and no satisfactory biomarkers are available for diagnosis before the end-stage. We explored serum peptide profiling for diagnosis and prediction of progression to liver failure in HBV-infected patients. Serum samples (164) fro...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01267.x

    authors: Han T,Liu H,Yu ZL,Li J,Wang L,Xiao SX,Li Y,Yu ML

    更新日期:2010-03-01 00:00:00

  • Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.

    abstract::Cognitive impairment occurs in 30%-50% of patients with non-cirrhotic chronic hepatitis C virus (HCV) infection. Exercise is beneficial in preventing and treating cognitive impairment and cardiometabolic abnormalities in many chronic inflammatory diseases, but there are few studies investigating the impact of exercise...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13460

    authors: O'Gorman P,Strahan O,Ferguson D,Monaghan A,Kennedy M,Forde C,Melo AM,Doherty DG,O'Brien KK,McKiernan S,Kenny RA,Coen R,Doherty C,Bergin C,Gormley J,Norris S

    更新日期:2020-12-28 00:00:00

  • Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection.

    abstract::Bacteremia has rarely been reported in patients receiving treatment for hepatitis C virus (HCV) infection. We describe the features and investigation of four cases of Staphylococcus aureus bacteremia occurring between 3 November 2004 and 10 January 2005 in patients on therapy for chronic HCV infection. The unusual occ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00828.x

    authors: Webster D,Ahmed R,Tandon P,Chui L,McDonald RR,Obarianyk A,Antonishyn N,Doucette K

    更新日期:2007-08-01 00:00:00

  • Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

    abstract::This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. HCV antibody-positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12758

    authors: Jacka B,Bray BC,Applegate TL,Marshall BDL,Lima VD,Hayashi K,DeBeck K,Raghwani J,Harrigan PR,Krajden M,Montaner JSG,Grebely J Senior

    更新日期:2018-01-01 00:00:00

  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

    abstract::The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13075

    authors: Idilman R,Demir M,Aladag M,Erol C,Cavus B,Iliaz R,Koklu H,Cakaloglu Y,Sahin M,Ersoz G,Koksal İ,Karasu Z,Ozgenel M,Turan İ,Gunduz F,Ataseven H,Akdogan M,Kiyici M,Koksal AS,Akhan S,Gunsar F,Tabak F,Kaymakoglu S

    更新日期:2019-06-01 00:00:00

  • Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D.

    abstract::Hepatitis delta virus (HDV) infection is a usually severe type of viral hepatitis associated with increased mortality and rapid evolution to cirrhosis. Currently, treatment is limited to extended interferon administration and measurement of HDV RNA blood levels is essential to judge the response. The aim of this study...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12000

    authors: Katsoulidou A,Manesis E,Rokka C,Issaris C,Pagoni A,Sypsa V,Hatzakis A

    更新日期:2013-04-01 00:00:00